PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

WDB coco Co., Ltd.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (14)

WDB coco Co., Ltd. owes ¥0.20 for every ¥1 it owns. Net profit fell 26% in the year to Mar 2026, and shrank 3% a year on average over 3 years.

Compared with Healthcare companies in Japan · latest annual results Mar 2026.

P/E ratio

9.4

Investors pay ¥9.4 for every ¥1 of WDB coco Co., Ltd.'s yearly profit, lower than 87% of Healthcare companies in Japan.

P/B ratio

1.31

The share price is 1.31 times WDB coco Co., Ltd.'s book value per share, lower than 62% of Healthcare companies in Japan.

Market cap

¥6.1 B

The total market value of all of WDB coco Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 73% of Healthcare companies in Japan. PosiCap size class: Micro Cap.

Net worth (book value)

¥4.7 B

What WDB coco Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

¥1,951

Net worth divided by the number of shares. The share price of ¥2,555 is 1.3 times this, which is the P/B above.

Return on equity (ROE)

14.6%

WDB coco Co., Ltd. earned 14.6% on its shareholders' money over the last year, higher than 81% of Healthcare companies in Japan.

Owes vs Owns

0.20×

WDB coco Co., Ltd. owes ¥0.20 for every ¥1 it owns (low), lower than 76% of Healthcare companies in Japan.

Dividend yield

3.91%

WDB coco Co., Ltd. pays 3.91% of its share price as dividends a year, higher than 83% of dividend-paying Healthcare companies in Japan.

Revenue growth

-10%

Revenue fell 10% in the year to Mar 2026, and grew 6% a year on average over 3 years.

Profit growth

-26%

Net profit fell 26% in the year to Mar 2026, and shrank 3% a year on average over 3 years.

Profit margin

14.1%

WDB coco Co., Ltd. keeps ¥14 of every ¥100 of revenue as net profit.

Cash quality

0.8×

Cash from WDB coco Co., Ltd.'s business was 0.8× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.

Interest cover

3724.5×

WDB coco Co., Ltd.'s operating profit covered its interest costs 3724.5 times in the year to Mar 2026.

Cash vs debt

Net cash

WDB coco Co., Ltd. held ¥3.7 B more cash than debt (net cash) at Mar 2026.

Questions

What is WDB coco Co., Ltd.'s P/E ratio?

Investors pay ¥9.4 for every ¥1 of WDB coco Co., Ltd.'s yearly profit, lower than 87% of Healthcare companies in Japan.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For WDB coco Co., Ltd.: ¥6.1 B ÷ ¥4.7 B (30 Jun 2026) = 1.3.

What is WDB coco Co., Ltd.'s return on equity?

WDB coco Co., Ltd. earned 14.6% on its shareholders' money over the last year, higher than 81% of Healthcare companies in Japan.

How much does WDB coco Co., Ltd. owe compared with what it owns?

WDB coco Co., Ltd. owes ¥0.20 for every ¥1 it owns (low), lower than 76% of Healthcare companies in Japan.

Does WDB coco Co., Ltd. pay a dividend?

Yes. WDB coco Co., Ltd. pays 3.91% of its share price as dividends a year, higher than 83% of dividend-paying Healthcare companies in Japan.

Is WDB coco Co., Ltd.'s revenue growing?

Revenue fell 10% in the year to Mar 2026, and grew 6% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.